Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
211 studies found for:    "Hemorrhagic fever"
Show Display Options
Rank Status Study
1 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Ribavirin
2 Not yet recruiting Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Condition: Viral Hemorrhagic Fever
Intervention: Drug: Ribavirin
3 Withdrawn Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Virazole (Ribavirin)
4 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
5 Enrolling by invitation Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
Conditions: Crimean-Congo Hemorrhagic Fever;   Lassa Fever
Intervention: Drug: Ribavirin (Virazole) Injection
6 Completed Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Biological: Vaccine/device combination for prevention of HFRS
7 Active, not recruiting Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: cAd3-EBOZ;   Biological: cAd3-EBO;   Biological: MVA-EbolaZ
8 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
9 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac
Condition: Hemorrhagic Fever, Ebola
Intervention: Procedure: blood sampling collection
10 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
11 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
12 Withdrawn A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
Condition: Ebola Hemorrhagic Fever
Interventions: Drug: AVI-7537;   Other: Normal Saline Solution (NSS)
13 Completed Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus
Condition: Ebola Hemorrhagic Fever
Interventions: Drug: Placebo;   Drug: AVI-6002
14 Active, not recruiting STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: rVSVΔG-ZEBOV
15 Completed Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: rVSVΔ-ZEBOV-GP
16 Completed Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus
Condition: Dengue Hemorrhagic Fever
Interventions: Biological: rDEN1delta30;   Biological: rDEN2/4delta30(ME);   Biological: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
17 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
18 Completed A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers
Condition: Marburg Hemorrhagic Fever
Interventions: Drug: AVI-7288;   Other: Placebo
19 Completed Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
Condition: Marburg Hemorrhagic Fever
Interventions: Drug: AVI-6003;   Drug: Placebo
20 Active, not recruiting Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults
Condition: Hemorrhagic Fever, Ebola
Intervention: Biological: HPIV3-EbovZ GP Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.